Literature DB >> 2503528

A rapid high-performance liquid chromatography assay of glibenclamide in serum.

M E Abdel-Hamid1, M S Suleiman, Y M el-Sayed, N M Najib, M M Hasan.   

Abstract

A rapid high-performance liquid chromatography (HPLC) determination of glibenclamide in human serum is described. Serum samples to which flufenamic acid has been added as internal standard were treated with acetonitrile as a protein precipitant. After centrifugation, separation and reconstitution, the redissolved residue was eluted from 5 mu Spherisorb C-8 reversed phase column at ambient temperature using a mobile phase consisting of acetonitrile-water (45:55 v/v) at pH 3.7-3.8 and pumped at a flow rate 2 ml/min. The effluent was monitored at 230 nm. The analysis time was no longer than 12 min. A linear relationship between the peak height ratio (glibenclamide/flufenamic acid) and concentration was obtained in the range 20-400 ng/ml. A typical calibration curve has a regression equation y = 0.0035x + 0.015 (r = 0.9999). The detection limit of glibenclamide in serum was 20 ng/ml. The mean recovery of drug from serum samples spiked with known amounts of glibenclamide was 96.77%. Within-day and between-day coefficients of variation were 1.6-4.0% and 1.4-3.5%, respectively. Stability testing indicated that glibenclamide was stable for at least 10 days in serum -20 degrees C. The method developed was applied to determine some pharmacokinetic parameters after the oral administration of 5 mg glibenclamide tablets to a human volunteer.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2503528     DOI: 10.1111/j.1365-2710.1989.tb00236.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  3 in total

1.  Glibenclamide in serum: comparison of high-performance liquid chromatography using fluorescence detector and liquid chromatography/mass spectrometry with atmospheric-pressure chemical-ionization (APCI LC/MS).

Authors:  F Susanto; H Reinauer
Journal:  Anal Bioanal Chem       Date:  1996-10       Impact factor: 4.142

2.  Glibenclamide in patients with poorly controlled type 2 diabetes: a 12-week, prospective, single-center, open-label, dose-escalation study.

Authors:  Virendra Rambiritch; Breminand Maharaj; Poobalan Naidoo
Journal:  Clin Pharmacol       Date:  2014-04-04

3.  Glibenclamide population pharmacokinetic/pharmacodynamic modeling in South African type 2 diabetic subjects.

Authors:  Virendra Rambiritch; Poobalan Naidoo; Goonaseelan Pillai
Journal:  Clin Pharmacol       Date:  2016-09-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.